Details of the Drug

General Information of Drug (ID: DML6XSP)

• Drug Name: Resiquimod
• Synonyms: Resiquimod [INN]; R 848; S 28463; R-848; S-28463; VML-600; 1-(4-Amino-2-ethoxymethyl-imidazo[4,5-c]quinolin-1-yl)-2-methyl-propan-2-ol; 1-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]-2-methylpropan-2-ol; 1-[4-amino-2-(ethoxymethyl)imidazo[4,5-c]quinolin-1-yl]-2-methylpropan-2-ol; 4-amino-2-(ethoxymethyl)-a,a-dimethyl-1h-imidazo[4,5-c]quinoline-1-ethanol; 4-amino-2-ethoxymethyl-alpha,alpha-dimethyl-1H-imidazo(4,5-c)quinoline-1-ethanol

Indication

Disease Entry	ICD 11	Status	REF
Actinic keratosis	EK90.0	Phase 2	[1]
Cutaneous T-cell lymphoma	2B01	Phase 2	[2]
Herpes simplex virus infection	1F00	Phase 1/2	[3]

• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 314.4
  Logarithm of the Partition Coefficient (xlogp); 1.3
  Rotatable Bond Count (rotbonds); 5
  Hydrogen Bond Donor Count (hbonddonor); 2
  Hydrogen Bond Acceptor Count (hbondacc); 5
• Chemical Identifiers:
  Formula: C17H22N4O2
  IUPAC Name: 1-[4-amino-2-(ethoxymethyl)imidazo[4,5-c]quinolin-1-yl]-2-methylpropan-2-ol
  Canonical SMILES: CCOCC1=NC2=C(N1CC(C)(C)O)C3=CC=CC=C3N=C2N
  InChI: InChI=1S/C17H22N4O2/c1-4-23-9-13-20-14-15(21(13)10-17(2,3)22)11-7-5-6-8-12(11)19-16(14)18/h5-8,22H,4,9-10H2,1-3H3,(H2,18,19)
  InChIKey: BXNMTOQRYBFHNZ-UHFFFAOYSA-N
• Cross-matching ID:
  PubChem CID: 159603
  ChEBI ID: CHEBI:36706
  CAS Number: 144875-48-9
  DrugBank ID: DB06530
  TTD ID: D0C8KF
• Repurposed Drugs (RPD): Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Toll-like receptor 7 (TLR7)	TTRJ1K4	TLR7_HUMAN	Modulator	[4]
Toll-like receptor 8 (TLR8)	TT8CWFK	TLR8_HUMAN	Modulator	[4]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Inhibitor of nuclear factor kappa-B kinase subunit beta (IKBKB)	OT9RDS3H	IKKB_HUMAN	Post-Translational Modifications	[5]
Interleukin-1 receptor-associated kinase 4 (IRAK4)	OT9JTJWC	IRAK4_HUMAN	Post-Translational Modifications	[5]
Interleukin-10 (IL10)	OTIRFRXC	IL10_HUMAN	Protein Interaction/Cellular Processes	[6]
Interleukin-12 subunit beta (IL12B)	OT0JF8A3	IL12B_HUMAN	Gene/Protein Processing	[7]
Interleukin-6 (IL6)	OTUOSCCU	IL6_HUMAN	Gene/Protein Processing	[5]
Tumor necrosis factor (TNF)	OT4IE164	TNFA_HUMAN	Gene/Protein Processing	[5]

Molecular Expression Atlas of This Drug

• The Studied Disease: Actinic keratosis
• ICD Disease Classification: EK90.0

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Toll-like receptor 7 (TLR7)	DTT	TLR7	3.32E-25	0.44	0.88

References

• [1] ClinicalTrials.gov (NCT01583816) Dose-finding, Safety, Efficacy Trial of Topical Resiquimod in Patients With Multiple Actinic Keratosis Lesions. U.S. National Institutes of Health.
• [2] ClinicalTrials.gov (NCT03292406) A Safety, Efficacy and Pharmacokinetics Study of CD11301 for the Treatment of Cutaneous T-Cell Lymphoma (CTCL) (CTCL). U.S. National Institutes of Health.
• [3] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5051).
• [4] TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848).Vaccine.2005 Nov 1;23(45):5263-70.
• [5] IRAK4 kinase activity controls Toll-like receptor-induced inflammation through the transcription factor IRF5 in primary human monocytes. J Biol Chem. 2017 Nov 10;292(45):18689-18698. doi: 10.1074/jbc.M117.796912. Epub 2017 Sep 18.
• [6] Generation and maturation of dendritic cells for clinical application under serum-free conditions. J Immunother. 2005 Nov-Dec;28(6):599-609. doi: 10.1097/01.cji.0000175491.21099.04.
• [7] Differential regulation of interleukin 12 and interleukin 23 production in human dendritic cells. J Exp Med. 2008 Jun 9;205(6):1447-61. doi: 10.1084/jem.20071450. Epub 2008 May 19.